{"id":"gsk5733584","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PDE4 inhibition leads to accumulation of cyclic adenosine monophosphate (cAMP) in immune and inflammatory cells, suppressing the production of pro-inflammatory cytokines and chemokines. This mechanism is intended to reduce excessive inflammatory responses in autoimmune and inflammatory diseases. The selective PDE4 inhibition aims to provide anti-inflammatory benefits while potentially minimizing off-target effects associated with broader phosphodiesterase inhibition.","oneSentence":"GSK5733584 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory signaling by increasing intracellular cAMP levels.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:14:39.542Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory bowel disease (Crohn's disease or ulcerative colitis)"}]},"trialDetails":[{"nctId":"NCT07286266","phase":"PHASE3","title":"A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-06-24","conditions":"Ovarian Neoplasms","enrollment":450},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT07286331","phase":"PHASE3","title":"A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-Endometrial01)","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-06-09","conditions":"Neoplasms, Endometrial","enrollment":600},{"nctId":"NCT06796907","phase":"PHASE1, PHASE2","title":"A Study of GSK5733584 in Combination With Anti-cancer Therapies for Advanced Solid Tumors","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-03-04","conditions":"Tumours, Gynecological","enrollment":392},{"nctId":"NCT06431594","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-07-02","conditions":"Solid Tumors, Neoplasms","enrollment":385}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GSK5733584","genericName":"GSK5733584","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GSK5733584 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory signaling by increasing intracellular cAMP levels. Used for Inflammatory bowel disease (Crohn's disease or ulcerative colitis).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}